<DOC>
	<DOCNO>NCT01344876</DOCNO>
	<brief_summary>To determine maximum tolerate dose ( MTD ) OPB-51602</brief_summary>
	<brief_title>Phase I Study OPB-51602 Patients With Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>1 . Patients confirm diagnosis MM , NHL , AML , ALL CML . 2 . Patients responsive relapse follow standard treatment 3 . Patients capable provide write informed consent 4 . Japanese patient age 20 75 year ( inclusive ) time inform consent 5 . ECOG performance status score 01 6 . Life expectancy least 3 month 7 . Adequate vital organ function 8 . Patients , together partner , willing capable use appropriate method contraception throughout trial period least 12 week final IMP administration 1 . Patients primary malignant tumor 2 . Symptomatic CNS involvement 3 . Ongoing active infection , complication controllable medication mean 4 . Complication uncontrolled cardiac disease 5 . Female patient pregnant , possibly pregnant , lactate , wish become pregnant study period 6 . Patients receive another study drug , receive chemotherapy , immunotherapy , cytokine therapy , surgery , radiotherapy treatment primary disease , within 4 week prior enrollment</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>multiple myeloma [ MM ]</keyword>
	<keyword>non-Hodgkin lymphoma [ NHL ]</keyword>
	<keyword>acute myeloid leukemia [ AML ]</keyword>
	<keyword>acute lymphoid leukemia [ ALL ]</keyword>
	<keyword>chronic myeloid leukemia [ CML ]</keyword>
</DOC>